BHB-1893 not checked

Braveheart Bio, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Cardiomyopathy, Hypertrophic Obstructive, Cardiomyopathy, Hypertrophic Non-Obstructive
Main trialPhase 3
“The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM). The trial includes adults who are currently being treated for oHCM or who have not yet been treated.”In the company’s words, NCT07755904 on ClinicalTrials.gov

Other drugs for Cardiomyopathy, Hypertrophic Obstructive

All 9 drugs for Cardiomyopathy, Hypertrophic Obstructive

Coming up2

Changes1

Last 90 days

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Oct 2028 BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Phase 3Not yet recruiting Dec 2029 BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BHB-1893

Following is part of Solo: you see every change to BHB-1893 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in